Clinical Trials
11
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
- Conditions
- Acute Ischemic Stroke
- Interventions
- Drug: Intravenous Placebo
- First Posted Date
- 2021-10-07
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Acticor Biotech
- Target Recruit Count
- 438
- Registration Number
- NCT05070260
- Locations
- 🇺🇸
Black Medical center, Bradenton, Florida, United States
🇺🇸Nova Clinical Research, Bradenton, Florida, United States
🇺🇸Northside hospital, Saint Petersburg, Florida, United States
Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19
- Conditions
- SARS-CoV InfectionAcute Respiratory Distress SyndromeCOVID-19ARDS
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- Acticor Biotech
- Target Recruit Count
- 60
- Registration Number
- NCT04659109
- Locations
- 🇫🇷
Hôpital de Hautepierre, Strasbourg, France
Acute Ischemic Stroke Interventional Study
- Conditions
- Acute Ischemic Stroke
- Interventions
- Other: Intravenous PlaceboDrug: Intravenous ACT017 1000 mg
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Acticor Biotech
- Target Recruit Count
- 160
- Registration Number
- NCT03803007
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de Bordeaux,, Bordeau, France
News
Acute Ischemic Stroke Pipeline Shows Promise with 25+ Therapies in Development and Recent Clinical Breakthroughs
DelveInsight's 2025 analysis reveals over 20 key companies are developing 25+ acute ischemic stroke therapies across various clinical phases, representing significant advancement in stroke treatment research.
Acticor Biotech Repositions Glenzocimab for Myocardial Infarction Treatment
Acticor Biotech is focusing on myocardial infarction with glenzocimab, encouraged by expert feedback on its potential in STEMI treatment.